Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03,...
Q1 2026
Mar 31, 2026
FY 2025
Mar 5, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 14, 2025